

Published in final edited form as:

ACS Chem Biol. 2012 October 19; 7(10): 1738–1745. doi:10.1021/cb300246j.

Ondansetron and Granisetron Binding Orientation in the 5-HT₃ Receptor Determined by Unnatural Amino Acid Mutagenesis

Noah H. Duffy[†], Henry A. Lester[‡], and Dennis A. Dougherty^{†,*}

[†]Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125

[‡]Division of Biology, California Institute of Technology, Pasadena, California 91125

Abstract

The serotonin type 3 receptor (5-HT₃R) is a ligand-gated ion channel that mediates fast synaptic transmission in the central and peripheral nervous systems. The 5-HT₃R is a therapeutic target, and the clinically available drugs ondansetron and granisetron inhibit receptor activity. Their inhibitory action is through competitive binding to the native ligand binding site, although the binding orientation of the drugs at the receptor has been a matter of debate. Here we heterologously express mouse 5-HT₃A receptors in *Xenopus* oocytes and use unnatural amino acid mutagenesis to establish a cation- π interaction for both ondansetron and granisetron to tryptophan 183 in the ligand binding pocket. This cation- π interaction establishes a binding orientation for both ondansetron and granisetron within the binding pocket.

INTRODUCTION

The serotonin type 3 receptor (5-HT₃R)^{1–2} is a ligand-gated ion channel in the Cys-loop (pentameric) family of receptors, which also includes GABA_A, glycine, and nicotinic acetylcholine (nACh) receptors.³ The 5-HT₃ receptor is a cation selective channel found in the central and peripheral nervous systems. Conduction occurs through a central pore, formed by the pseudo-symmetric assembly of five subunits (Figure 1). There are five known 5-HT₃R subunits (A – E),⁴ with the best characterized receptors being the homomeric 5-HT₃A receptor (5-HT₃AR) and the heteromeric 5-HT₃AB receptors.⁵

The 5-HT₃ receptor has been validated as a therapeutic target—antagonists are currently used to control chemotherapy-induced nausea, as well as to treat irritable bowel syndrome.^{6–7} Beyond current clinical uses, there is evidence that compounds targeting the 5-HT₃ receptor could be useful for the treatment of a variety of disorders including schizophrenia and substance abuse, as well as management of pain associated with, for example, fibromyalgia. Prototype antagonists of the 5-HT₃ receptor are ondansetron (Zofran®) and granisetron (Kytril®) (Figure 2a).

There is no high-resolution structure of the 5-HT₃ receptor. There is, however, structural information from a number of sources, including cryoelectron microscopy images of the nACh receptor,⁸ high resolution structures of the homologous acetylcholine binding protein,⁹ and the recently published x-ray structure of the glutamate-gated chloride channel from *C. elegans*, GluCl.¹⁰ These data, along with homology modeling and biochemical studies, have provided a putative binding site for 5-HT₃ antagonists that coincides with the binding site of the native agonist, serotonin (5-HT, Figure 2b). This binding site is formed

*Corresponding Author. dadougherty@caltech.edu.

by a series of β -strands and connecting loops (labeled A-F), with loops A-C contributed by the “principal,” and β -strands D-F contributed by the “complementary” subunit (Figure 1). Docking studies using homology models have found multiple energetically favorable poses of the antagonist granisetron within this binding site, and the orientation of the drug and the identities of the interacting residues are not constant across poses.^{11–14} For example, Thompson *et. al.* reported two classes of poses of granisetron.¹³ In one class, the cationic ammonium was oriented between Trp183 (loop B) and Tyr234 (loop C), while the aromatic indazole was oriented between Trp90 (β -strand D) and Phe226 (loop C). In the second class of poses, this orientation was reversed, with the cationic ammonium towards Trp90 and Phe226. Experimentally, both Trp183 and Trp90 have been established to be important for granisetron binding. In other experimental work, Yan and White found that Trp90 is important for both ondansetron and granisetron binding, and they interpreted their results as providing evidence that the cationic ammonium of granisetron was oriented towards Trp90.¹⁴

The accepted pharmacophore model for 5-HT₃R includes an amine group on the ligand. Past studies in our laboratory have established the primary amine of 5-HT to make a cation- π interaction with a conserved tryptophan residue on loop B (Trp183).¹⁵ Mutation of Trp183 (as well as Trp90, Glu129 (loop A), and Tyr234) to alanine abolishes binding of [³H]granisetron.¹³ Taken together, these results identify Trp183 as a prime candidate for more detailed studies. Moreover, the docking studies of Thompson *et. al.* provide us with testable guidelines as to other possible interactions; specifically, with Trp90.¹³ In the present work, we set out to better understand the binding of the high affinity antagonistic drugs ondansetron and granisetron to the 5-HT₃AR. The cationic center of granisetron is a tertiary ammonium ion in a granatane moiety ($pK_a = 9.6$), but ondansetron has a structurally distinct *N*-akylimidazolium moiety ($pK_a = 7.4$).¹⁶ We sought to determine if this structural difference leads to different binding orientations for the two drugs.

RESULTS AND DISCUSSION

Ondansetron and Granisetron Schild Analysis

In examining the interaction of a competitive antagonist with a receptor, equilibrium dissociation constants, K_b , provide the most direct indicator of binding interactions.¹⁷ Previous reports have indicated that granisetron and ondansetron act competitively with 5-HT at the 5-HT₃AR.^{2, 18} Both antagonists bind reversibly, in that after a several minute washout of either ondansetron or granisetron, agonist responses recovered completely. Previous studies have established dissociation rate constants of 0.58 min⁻¹ for ondansetron, and 0.13 min⁻¹ for granisetron,¹⁹ consistent with our observations. It has also been shown that granisetron and ondansetron directly compete with each other for the same binding site.¹⁹ We attempted to determine K_b for ondansetron and granisetron using Schild (dose-ratio) analysis;¹⁷ this requires measurements of dose-response relationships (Figure 3). Schild analysis of ondansetron applied to preparations of rat vagus nerves gave parallel shifts, indicative of a competitive interaction, but efforts to perform similar studies with granisetron were not successful.²⁰ As shown in Figure 3, during our standard 15 second agonist application (see Methods), the inhibition by ondansetron and granisetron was insurmountable by 5-HT—full receptor activity could not be restored even with high concentrations of 5-HT. We attribute the insurmountable inhibition to the slow off rates. The granisetron data are better behaved than the ondansetron data, but in either case we face a requirement of agonist applications several minutes in duration. However, the 5-HT₃AR desensitizes on this time scale before full equilibrium is achieved. Thus, for the high-affinity 5-HT₃AR antagonists ondansetron and granisetron, determination of true K_b by functional measurements is not possible.

Thus, the concentration required for 50% receptor inhibition (IC_{50}) was the only viable functional measurement, and so modified procedures were developed to render IC_{50} values a good direct measure of antagonist binding. The IC_{50} measurement is taken in the context of multiple equilibria, including both agonist and antagonist binding/dissociation, conformational changes in the protein, and the “gating” equilibria between the open the closed states of the receptor. We sought to reduce the contribution from changes in *agonist* potency, while retaining an index of *antagonist* potency. When evaluating competitive antagonists, it is useful to consider more than one agonist, so that one can be sure that IC_{50} determinations are not distorted by agonist-receptor interactions. To determine IC_{50} values for ondansetron and granisetron, we studied both 5-HT and an additional agonist, *meta*-chlorophenylbiguanide (mCPBG, Figure 2b).²¹

Agonist behavior at Trp183 and Trp90. The effective concentrations for 50% receptor activation (EC_{50}) were determined for both the native agonist 5-HT, as well as the potent partial agonist mCPBG. The EC_{50} values were also determined for a series of fluorinated tryptophan derivatives (Figure 2c) introduced by nonsense suppression at Trp183 (Table 1). The EC_{50} values confirm the previously reported¹⁵ cation- π interaction for 5-HT at Trp183. Interestingly, we have recently found that mCPBG does not respond to fluorination at Trp183 in the same manner as 5-HT,²² and the data of Table 2 produced for this work confirm that result. Detailed experiments and discussion concerning the activation of 5-HT₃ receptors by mCPBG will be presented in a separate publication.²² For the present purposes, the key point is that mCPBG responds for fluorination at Trp183 differently than 5-HT.

When the fluorinated tryptophans F₃Trp and F₄Trp were installed at Trp90, both 5-HT and mCPBG show a *gain* of function. These data are consistent with no cation- π interaction for 5-HT or mCPBG with Trp90.

Ondansetron and Granisetron at Trp183 and Trp90

An important aspect of the complex nature of measuring IC_{50} in receptors is the concentration of agonist used for receptor activation. For a competitive interaction, a measured IC_{50} value will depend on the agonist concentration.¹⁷ In order to make meaningful comparisons of IC_{50} values across mutant receptors, the concentration of agonist used was kept at a constant value of twice EC_{50} . The choice of a constant ratio of twice EC_{50} was made to ensure sufficient signal, even in cases of low receptor expression. We also emphasize that the series of mutations being introduced represents a much more subtle variation in structure than is possible with conventional mutagenesis. This provides further confidence that no dramatic changes in receptor-antagonist interactions are occurring in the study. We also exploited the difference in the binding modes of 5-HT and mCPBG to control for possible artificial trends in IC_{50} measurements.

Dose-response/inhibition relations were determined for ondansetron and granisetron, using both 5-HT and mCPBG as agonists, with representative voltage-clamp traces shown in Figure 4. These measurements were performed on the wild type 5-HT₃AR as well as for a series of fluorinated tryptophan derivatives at Trp183. Agonist concentrations were $2 \times EC_{50}$ for each agonist at each receptor, and data were fit to the Hill equation (Figure 4). The resultant IC_{50} values are presented in Table 2. Inhibition data for F₄Trp could not be gathered using 5-HT as the agonist, because of channel block by high concentrations of 5-HT.

The effect of fluorine substitution in modulating a cation- π interaction has been well established.^{15, 23–25} For both ondansetron and granisetron, incremental substitutions of fluorine to Trp183 increased IC_{50} . As in previous studies of fluorination trends, IC_{50} fold-shift values were plotted against cation- π binding ability of fluorinated indoles, producing

the “fluorination plots” shown in Figure 5. Ondansetron inhibition linearly correlates with the energy of cation- π binding, regardless of whether 5-HT or mCPBG was used as an agonist. Granisetron also displayed a strong correlation with respect to degree of fluorination, regardless of agonist identity.

We interpret these results as establishing a cation- π interaction between each drug and Trp183. The results of Figure 5 highlight the value of having two distinct agonists to evaluate an antagonist. With 5-HT as the agonist, we see linear fluorination plots for the antagonists. The agonist alone, 5-HT, shows a similar plot in a study of its EC₅₀. We corrected for this by always using a 5-HT dose of $2 \times$ EC₅₀ for the particular fluorination mutant. Nevertheless, there could be concern about deconvoluting the effect of fluorination on the agonist vs. the antagonist. With mCPBG as the agonist, there is no such concern, as it does not respond to fluorination at Trp183 in a manner consistent with a cation- π interaction. Thus, the fluorination trends seen in Figure 5 can confidently be assigned as reflecting the response of the antagonist to the mutation. We also note that the fluorination effect remains regardless of the structural identity of the cation. Ondansetron, with a *N*-alkylimidazolium moiety, and granisetron, with a tertiary ammonium, show similar trends at the same residue, which is evidence that their binding orientations are similar.

While the general trends in our data are clear, the detailed behaviors of the F₂Trp unnatural amino acids present interesting details. In the fluorination plots, 5,7-F₂Trp, a residue that we have used extensively, deviates from the line set by the other derivatives, especially for granisetron. The effect is evident, but much less pronounced, in studies of ondansetron. We considered the possibility that an additional unique, perhaps steric, feature of 5,7-F₂Trp was influencing the analysis.

As such, we prepared 4,7-F₂Trp (Scheme 1), which should have the same cation- π binding ability, but different steric requirements. Synthesis began by direct formation of 4,7-difluoroindole (**1**) in a Bartoli reaction between the appropriate nitrodifluorobenzene and vinyl magnesium bromide.^{26–27} In a sequence similar to Gilchrist *et. al.*²⁸ the difluoroindole (**1**) was then reacted with ethyl-3-bromo-2-hydroxyiminopropanoate to yield the oxime (**2**), which was then reduced using aluminum/mercury amalgam. The amine of the resulting amino acid ester was protected with the photocleavable 2-nitroveratryloxycarbonyl (NVOC), and the ester hydrolyzed with sodium hydroxide. Conversion to the cyanomethyl ester (**3**) gave material suitable for acylation of the dinucleotide dCA, and for preparation of tRNA necessary for incorporation into the 5-HT₃R (methods described previously).²⁹ The unnatural amino acid prepared by this route is, of course, racemic, but only the natural L configuration will be incorporated; the ribosome of the *Xenopus* oocyte in effect performs a kinetic resolution.

From an electrostatic point of view, 5,7-F₂Trp and 4,7-F₂Trp are, to first order, indistinguishable, and so they should be equivalent in a cation- π interaction. This is born out in the EC₅₀ data for serotonin (Table 1), where the two F₂Trp residues differ only by a factor of two, while the full fluorination series spans more than a factor of 150. In contrast, the EC₅₀ values for mCPBG differ by 8-fold for the two F₂Trps. Recall that mCPBG does not make a cation- π interaction to the Trp. This again suggests that specific steric interactions at Trp183 may be involved.

In the granisetron IC₅₀ plots, 4,7-F₂Trp gives a quite different response than 5,7-F₂Trp. We have suggested the possibility of a special steric effect with 5,7-F₂Trp, but 5,6,7-F₃Trp and 4,5,6,7-F₄Trp both have fluorine atoms at the positions in 5,7-F₂Trp, yet follow the trend indicative of electrostatics as the major determinant to binding. As such, we cannot provide a simple rationalization of the behaviors of the two difluoro-Trp residues. Nevertheless, the

consistent linear trend of Trp, F₁Trp, F₃Trp, and F₄Trp (Figure 5) provides compelling evidence for a cation- π interaction to Trp183 for both granisetron and ondansetron.

Both ondansetron and granisetron either increase their potencies or retain their potencies when Trp90 is mutated to F₃Trp or F₄Trp respectively. This holds for both 5-HT and mCPBG used as the agonist, which indicates no cation- π interaction at that site. A loss of potency would be expected if a cation- π interaction were present. We noted above that Yan and White concluded that Trp90 is important for binding of ondansetron and granisetron.¹⁴ Based on the observation that granisetron and ondansetron responded differently to a W90F mutation, the authors concluded that the bicyclic amine of granisetron interacts with Trp90. Our results position this moiety in contact with Trp183, and we conclude that the importance of Trp90 is for reasons other than a cation- π interaction.

The present results provide evidence that the cationic centers of ondansetron and granisetron are oriented towards Trp183, and not towards Trp90. Establishing a cation- π interaction with ondansetron and granisetron at Trp183 determines a binding orientation for these antagonists. Docking studies of granisetron performed in other laboratories have generated a series of poses, some which are consistent with the cation pointed towards Trp183. Our data provide evidence that these poses are the most viable, while those with the cation pointed away from Trp183 are not likely to be relevant.

Summary

We have identified a cation- π interaction with the antagonists ondansetron and granisetron to Trp183 in the 5-HT₃AR. This interaction is consistent with the binding mode of 5-HT, but not mCPBG. The use of agonists with alternate binding modes validates our data as direct measurements of ondansetron and granisetron. Thus, the common antagonists follow the basic pharmacophore established by 5-HT, and not the structurally dissimilar agonist mCPBG.

METHODS

Procedures for incorporating unnatural amino acids, expressing receptors in *Xenopus* oocytes, and characterization by electrophysiology followed established protocols.²⁹

Protein expression in *Xenopus* oocytes

The mouse 5-HT₃A receptor in the pGEMHE vector was linearized with the restriction enzyme *Sbf*I (New England Biolabs). mRNA was prepared by in vitro transcription using the mMessage Machine T7 kit (Ambion). Unnatural mutations were introduced by the standard Stratagene QuickChange protocol using a TAG mutation at W183 and W90. Stage V-VI *Xenopus laevis* oocytes were injected with mRNA. Each cell was injected with 50 nL containing only mRNA (5 ng) for wild type 5-HT₃AR or a mixture of mRNA (5–32 ng, typically ~12 ng) and tRNA (18–30 ng, typically ~18 ng) for unnatural amino acid. Uncharged full length tRNA was injected as a negative control.

Electrophysiology—Electrophysiological experiments were performed 24–48 hours after injection using the OpusXpress 6000A instrument (Axon Instruments) in two-electrode voltage clamp mode at a holding potential of –60 mV. The running buffer was Ca²⁺-free ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl₂ and 5 mM HEPES, pH 7.5). Serotonin hydrochloride (5-HT) was purchased from Alfa Aesar. 1-(3-Chlorophenyl)biguanide (mCPBG) was purchased from Sigma-Aldrich. Granisetron hydrochloride and ondansetron hydrochloride were purchased from Tocris Bioscience.

For EC₅₀ determinations, oocytes were superfused with running buffer at 1 mL/min for 30s before application of 5-HT or mCPBG for 15 s followed by a 116 s wash with the running buffer. Data were sampled at 125 Hz and filtered at 50 Hz. Dose-response data were obtained for 9 concentrations of 5-HT or mCPBG on 9 cells. All EC₅₀ and Hill coefficient values were obtained by fitting dose-response relations to the Hill equation ($I_{\text{norm}} = 1/[1 + (EC_{50}/[\text{agonist}])^n]$) and are reported as means \pm standard error of the fit.

For IC₅₀ determinations, oocyte response to either 5-HT or mCPBG at $2 \times EC_{50}$ for each receptor was measured before application of antagonists by application of the agonist for 15 s followed by 116 s of wash with the running buffer. Granisetron or ondansetron doses were then pre-applied and the oocyte allowed to incubate for 60 s, followed by application of a mixture of the antagonist dose with 5-HT or mCPBG at 2 fold EC₅₀. The oocytes were then washed with the running buffer for 116 s. Every 4 antagonist doses, the oocytes were washed for 10 min, and oocyte response reconfirmed using either 5-HT or mCPBG at 2 fold EC₅₀. Oocytes that did not give consistent responses to 5-HT or mCPBG alone throughout the experiment were discarded. Dose-response data were obtained for 8 concentrations of granisetron or ondansetron on 8 cells. All EC₅₀ and Hill coefficient values were obtained by fitting Dose-response relations to the Hill equation ($I_{\text{norm}} = 1/[1 + (EC_{50}/[\text{antagonist}])^n]$) and are reported as means \pm standard error of the fit.

For Schild analysis, the protocol for EC₅₀ determinations was repeated with the following changes: during the course of the experiment after each minimal EC₅₀ curve was determined, running buffer containing granisetron or ondansetron was used for the subsequent EC₅₀ determinations. Agonist applications in the subsequent EC₅₀ determinations contained the same concentration of antagonist as the running buffer.

Synthesis of 3 (Scheme 1)

4,7-Difluoroindole (1)—A solution of 3.5 mL (32.3 mmol) of 1,4-difluoro-2-nitrobenzene in 30 mL of dry THF was cooled in an acetone/dry ice bath to -78°C under argon. A 1 M solution of vinylmagnesium bromide in THF (100 mL, 100 mmol, 3 eq.) was added via cannula over 20 minutes. The reaction was stirred for 1 hour at -78°C . Reaction quenched by the addition of 20 mL of saturated aq. NH₄Cl. Upon warming to room temperature, 20 mL of water was added, which forms a thick emulsion. Reaction filtered through a layer of sand and washed copiously with ethyl acetate. The organic layer was separated and dried over Na₂SO₄. The solvent was removed under reduced pressure to yield a brown oil containing multiple compounds. Purification by silica gel chromatography using a gradient of 3% to 10% ethyl acetate in hexanes yielded a slightly volatile amber oil. 871 mg (18%). Silica TLC (4% EtOAc in hexanes) R_f = 0.26, stains red/pink using *p*-anisaldehyde. ¹H NMR (300 MHz, CDCl₃): δ 8.47 (br, 1H), 7.18 (t, *J* = 2.8 Hz, 1H), 6.78 (ddd, *J* = 10.3, 8.6, 3.5 Hz, 1H), 6.71 – 6.60 (m, 2H). ¹⁹F NMR (282 MHz, CDCl₃): δ -124.1 – -129.8 (m), -139.4 – -142.3 (m). ¹³C NMR (126 MHz, CDCl₃): δ 152.2 (dd, *J* = 239, 2.4 Hz), 145.8 (dd, *J* = 238.6, 3.0 Hz), 126.0 (dd, *J* = 15.9, 11.5 Hz), 124.7, 119.9 (dd, *J* = 24.9, 5.7 Hz), 106.4 (dd, *J* = 18.9, 8.2 Hz), 103.9 (dd, *J* = 18.9, 8.2 Hz), 99.8. HRMS EI(+) *m/z* for C₈H₅NF₂ found 153.0395, calculated 153.0390 (M+•).

Ethyl 3-(4,7-difluoro-1H-indol-3-yl)-2-(hydroxyimino)propanoate (2)—A solution of 424 mg (2.8 mmol, 2 eq.) of 4,7-difluoroindole in 10 mL CH₂Cl₂ was added to 290 mg (1.4 mmol, 1 eq.) of ethyl 3-bromo-2-(hydroxyimino)propanoate and 205 mg (1.9 mmol, 1.4 eq.) of Na₂CO₃. The mixture was stirred overnight under argon at room temperature. The reaction was diluted with 50 mL of CH₂Cl₂ and 50 mL of ethyl acetate, washed with 50 mL of water, 50 mL brine. The organic phase was separated and dried over Na₂SO₄. Purification performed by silica chromatography, gradient 25% to 40% EtOAc in hexanes to yield a

white solid. 195 mg (50%). ¹H NMR (300 MHz, CD₃CN): δ 9.93 (s, 1H), 9.64 (br, 1H), 7.01 (m, 1H), 6.81 (ddd, *J* = 10.5, 8.5, 3.5 Hz, 1H), 6.67 (ddd, *J* = 10.7, 8.5, 3.2 Hz, 1H), 4.21 (q, *J* = 7.2 Hz, 2H), 4.12 (d, *J* = 1.1 Hz, 2H), 1.23 (t, *J* = 7.1 Hz, 3H). ¹⁹F NMR (282 MHz, CD₃CN): δ -130.99 – -131.20 (m), -141.02 – -141.19 (m). ¹³C NMR (126 MHz, CDCl₃): δ 164.80, 153.77 (dd, *J* = 240.4, 2.3 Hz), 152.58, 146.84 (dd, *J* = 238.1, 2.9 Hz), 127.18 (dd, *J* = 16.4, 12.1 Hz), 125.12, 119.55 (dd, *J* = 22.1, 5.7 Hz), 110.05 (dd, *J* = 3.7, 1.6 Hz), 106.94 (dd, *J* = 19.7, 9.1 Hz), 104.42 (dd, *J* = 22.9, 7.5 Hz), 62.28, 21.96 (d, *J* = 3.1 Hz), 14.33. HRMS FAB(+) *m/z* for C₁₃H₁₃O₃N₂F₂ found 283.0888, calculated 283.0894 (M+H).

N-(2-nitroveratryloxycarbonyl)-4,7-difluorotryptophan cyanomethyl ester (3)—

In a beaker 1.5 g of 8–20 mesh aluminum stirred under 15 mL of 2 M NaOH for 5 minutes. After decanting, the aluminum was rinsed with water and 15 mL of a 2% HgCl₂ solution was added and stirred slowly. The solution was decanted after formation of the Hg-Al (~10 minutes) and added to 195 mg (0.69 mmol) of **2** in 20 mL of 9:1 dioxane:water. The reaction was stirred slowly at room temperature overnight (~24 hours). The reaction was filtered through fluted paper, then applied to a silica plug, eluting with EtOAc followed by 4% MeOH in EtOAc. After concentration under reduced pressure, the resulting oil was used directly. The oil was dissolved in 20 mL of 1:1 THF:water and 151 mg of Na₂CO₃ (1.42 mmol) and 248 mg of 4,5-dimethoxy-2-nitrobenzyl chloroformate (0.9 mmol) were added. The reaction was stirred at room temperature for 3 hours, followed by dilution with 20 mL CH₂Cl₂ and 20 mL 1 N HCl. The organic phase was separated, washed with brine, and dried over Na₂SO₄. Initial purification by silica chromatography 20% to 40% EtOAc in hexanes did not separate the product from nitroveratryl side products. This mixture was dissolved in 3 mL dioxane and 3 mL 2N NaOH and stirred for 15 minutes. Reaction quenched with 6 mL 1 N HCl and diluted with 20 mL EtOAc. The organic phase was separated, and the aqueous phase washed with 20 mL CH₂Cl₂. The combined organic phases were dried over Na₂SO₄, concentrated under reduced pressure, and filtered through a silica plug eluting EtOAc followed by 0.5 % acetic acid in EtOAc. This residue (~35 mg, 0.07 mmol) was dissolved in 1 mL DMSO, and added to a reaction flask containing 0.5 mL of chloroacetonitrile (7.9 mmol), and 0.5 mL of triethylamine (3.6 mmol). The reaction was allowed to stir at room temperature for 5 hours. The reaction was poured onto a dry column of silica and eluted with EtOAc to recover 23 mg of a yellow solid (6%, 4 steps). ¹H NMR (300 MHz, DMSO-*d*₆): δ 11.71 (s, 1H), 8.21 (d, *J* = 7.7 Hz, 1H), 7.68 (s, 1H), 7.23 (d, *J* = 2.0 Hz, 1H), 7.09 (s, 1H), 6.92 – 6.80 (m, 1H), 6.74 – 6.62 (m, 1H), 5.39 – 5.21 (m, 2H), 4.99 (s, 2H), 4.48 – 4.35 (m, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.32 – 2.99 (m, 2H). ¹⁹F NMR (282 MHz, DMSO-*d*₆): δ -130.18 (dd, *J* = 22.4, 9.9 Hz), -138.53 (ddd, *J* = 22.6, 10.6, 3.1 Hz). ¹³C NMR (126 MHz, DMSO-*d*₆): δ 171.56, 156.03, 153.83, 152.62 (d, *J* = 239.6 Hz), 148.15, 146.10 (dd, *J* = 238.5, 2.2 Hz), 139.55, 128.09, 126.70 (dd, *J* = 16.1, 12.2 Hz), 126.36, 118.82 – 118.30 (m), 116.08, 110.61, 109.18, 108.59, 106.23 (dd, *J* = 18.8, 8.7 Hz), 103.90 – 103.23 (m), 63.15, 56.55, 55.30, 49.97, 27.84. HRMS FAB(+) *m/z* for C₂₃H₂₀O₈N₄F₂ found 518.1271, calculated 518.1249 (M+•).

Acknowledgments

We thank S. Lummis for helpful discussions and input. This work was supported by the NIH (NS 34407 and DA19375).

References

- Nichols DE, Nichols CD. Serotonin receptors. *Chem Rev.* 2008; 108:1614–1641. [PubMed: 18476671]
- Thompson AJ, Lummis SCR. 5-HT₃ receptors. *Curr Pharm Design.* 2006; 12:3615–3630.

3. Thompson AJ, Lester HA, Lummis SCR. The structural basis of function in Cys-loop receptors. *Q Rev Biophys.* 2010; 43:449–499. [PubMed: 20849671]
4. Niesler B, Walstab J, Combrink S, Moller D, Kapeller J, Rietdorf J, Bonisch H, Gothert M, Rappold G, Bruss M. Characterization of the novel human serotonin receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E. *Mol Pharmacol.* 2007; 72:8–17. [PubMed: 17392525]
5. Jensen AA, Davies PA, Brauner-Osborne H, Krzywkowski K. 3B but which 3B? And that's just one of the questions: the heterogeneity of human 5-HT(3) receptors. *Trends Pharmacol Sci.* 2008; 29:437–444. [PubMed: 18597859]
6. Machu TK. Therapeutics of 5-HT3 receptor antagonists: Current uses and future directions. *Pharmacol Ther.* 2011; 130:338–347. [PubMed: 21356241]
7. Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Expert opinion on therapeutic targets. 2007; 11:527–40. [PubMed: 17373882]
8. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4 angstrom resolution. *J Mol Biol.* 2005; 346:967–989. [PubMed: 15701510]
9. Hibbs RE, Sulzenbacher G, Shi JX, Talley TT, Conrod S, Kem WR, Taylor P, Marchot P, Bourne Y. Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha 7 nicotinic acetylcholine receptor. *Embo J.* 2009; 28:3040–3051. [PubMed: 19696737]
10. Hibbs RE, Gouaux E. Principles of activation and permeation in an anion-selective Cys-loop receptor. *Nature.* 2011; 474:54–60. [PubMed: 21572436]
11. Joshi PR, Suryanarayanan A, Hazai E, Schulte MK, Maksay G, Bikadi Z. Interactions of Granisetron with an agonist-free 5-HT3A receptor model. *Biochemistry.* 2006; 45:1099–1105. [PubMed: 16430206]
12. Maksay G, Bikadi Z, Simonyi M. Binding interactions of antagonists with 5-hydroxytryptamine(3A) receptor models. *J Recept Signal Transduct.* 2003; 23:255–270.
13. Thompson AJ, Price KL, Reeves DC, Chan SL, Chau PL, Lummis SCR. Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding. *J Biol Chem.* 2005; 280:20476–20482. [PubMed: 15781467]
14. Yan D, White MM. Spatial orientation of the antagonist granisetron in the ligand-binding site of the 5-HT3 receptor. *Mol Pharmacol.* 2005; 68:365–371. [PubMed: 15914697]
15. Beene DL, Brandt GS, Zhong WG, Zacharias NM, Lester HA, Dougherty DA. Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: The anomalous binding properties of nicotine. *Biochemistry.* 2002; 41:10262–10269. [PubMed: 12162741]
16. Delorenzi FG, Bridal TR, Spinelli W. Block of the Delayed Rectifier Current (I-K) by the 5-HT3 Antagonists Ondansetron and Granisetron in Feline Ventricular Myocytes. *Br J Pharmacol.* 1994; 113:527–535. [PubMed: 7834204]
17. Wyllie DJA, Chen PE. Taking the time to study competitive antagonism. *Br J Pharmacol.* 2007; 150:541–551. [PubMed: 17245371]
18. Barnes NM, Hales TG, Lummis SCR, Peters JA. The 5-HT3 receptor - the relationship between structure and function. *Neuropharmacology.* 2009; 56:273–284. [PubMed: 18761359]
19. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. *Anesth Analg.* 2008; 107:469–478. [PubMed: 18633025]
20. Ito H, Akuzawa S, Tsutsumi R, Kiso T, Kamato T, Nishida A, Yamano M, Miyata K. Comparative Study of the Affinities of the 5-HT3 Receptor Antagonists, YM060 YM114 (KAE-393), Granisetron and Ondansetron in Rat Vagus Nerve and Cerebral Cortex. *Neuropharmacology.* 1995; 34:631–637. [PubMed: 7566499]
21. Kilpatrick GJ, Butler A, Burridge J, Oxford AW. 1-(m-Chlorophenyl)-Biguanide, a Potent High-Affinity 5-HT3 Receptor Agonist. *Eur J Pharmacol.* 1990; 182:193–197. [PubMed: 2144822]
22. Miles TF, Bower KS, Lester HA, Dougherty DA. A coupled array of noncovalent interactions impacts the function of the 5-HT3A serotonin receptor in an agonist-specific way. 2012 in press. 10.1021/cn3000586

23. Xiu XA, Puskar NL, Shanata JAP, Lester HA, Dougherty DA. Nicotine binding to brain receptors requires a strong cation- π interaction. *Nature*. 2009; 458:534–537. [PubMed: 19252481]
24. Dougherty DA. Physical organic chemistry on the brain. *J Org Chem*. 2008; 73:3667–73. [PubMed: 18412391]
25. Dougherty DA. Cys-loop neuroreceptors: structure to the rescue? *Chem Rev*. 2008; 108:1642–53. [PubMed: 18447378]
26. Choi-Sledeski, Y-M.; Gardner, CJ.; Liang, G.; Poli, GB.; Shum, PW-K.; Stoklosa, GT.; Zhao, Z. (Sanofi-Aventis, Fr.) Preparation of aminomethylphenylpiperidinylindolylmethanone derivatives for use as tryptase inhibitors. Patent WO 2011022449..
27. Ricci A, Fochi M. Reactions between organomagnesium reagents and nitroarenes: Past, present, and future. *Angew Chem-Int Edit*. 2003; 42:1444–1446.
28. Gilchrist TL, Lingham DA, Roberts TG. Ethyl 3-Bromo-2-hydroxyiminopropanoate, a Reagent for the Preparation of Ethyl Esters of Alpha-Amino Acids. *J Chem Soc-Chem Commun*. 1979:1089–1090.
29. Nowak MW, Gallivan JP, Silverman SK, Labarca CG, Dougherty DA, Lester HA. In vivo incorporation of unnatural amino acids into ion channels in *Xenopus* oocyte expression system. *Methods Enzymol*. 1998; 293:504–529. [PubMed: 9711626]




Figure 1. Basic layout of a Cys-loop (pentameric) receptor. The structure is that of the GluCl α subunit¹⁰ (pdb 3RIF). Left: The full receptor, with two subunits are highlighted; one (blue) contributes principal agonist binding site residues, found on loops A (red), B (green), and C (blue). The complementary subunit (black) contributes loops D (purple), E (orange), and F (yellow). The α -helical region corresponds to the transmembrane domain; the region above it is extracellular. Right: Detail of agonist binding site, noting approximate locations of key residues considered here.





Figure 2. Chemical structures of drugs and amino acids used in this study. (a) 5-HT_{3A} receptor antagonists. (b) 5-HT_{3A} receptor agonists. (c) Tryptophan analogs.

**Figure 3.**

Dose-response curves of wild-type 5-HT_{3A} receptor. Responses to 5-HT with increasing concentrations of: (a) ondansetron, and (b) granisetron. Data fit to the Hill equation. Fit parameters: (a) Mean maximal current: $8 \pm 4 \mu\text{A}$. [ondansetron] = 0 nM, EC_{50} : $1.3 \pm 0.2 \mu\text{M}$, n_H : 2.4 ± 0.6 ; [ondansetron] = 0.64 nM, I_{max} : 63%, EC_{50} : $1.1 \pm 0.4 \mu\text{M}$, n_H : 2 ± 1 ; [ondansetron] = 4.5 nM, I_{max} = 61%, EC_{50} : $9 \pm 29 \mu\text{M}$, n_H : 2 ± 8 . (b) Mean maximal current: $9 \pm 4 \mu\text{A}$. [granisetron] = 0 nM, EC_{50} : $1.5 \pm 0.1 \mu\text{M}$, n_H : 2.0 ± 0.1 ; [granisetron] = 0.6 nM, I_{max} : 25%, EC_{50} : $0.7 \pm 0.7 \mu\text{M}$, n_H : 2 ± 7 ; [granisetron] = 1.2 nM, I_{max} : 4%, EC_{50} : $1 \pm 1 \mu\text{M}$, n_H : 1 ± 2 .




Figure 4. Representative voltage-clamp traces and dose-inhibition curves for antagonists for wild type and Trp183 mutant 5-HT₃A receptors. Representative traces for inhibition of (a) wild-type and (b) W183F₃W receptors by increasing doses of granisetron. Time of application and concentration noted by black bars. Channels opened by addition of mCPBG (red bars) at (a) 1 μ M and (b) 13 μ M. Hashes indicate wash times. Ondansetron inhibition curves shown for receptors activated by (c) mCPBG, and (d) 5-HT. Granisetron inhibition curves shown for receptors activated by (e) mCPBG, and (f) 5-HT. Data fit to the Hill equation; fit parameters (IC_{50} and n_H) are in Table 2.




Figure 5. Fluorination plots. Calculated cation- π binding ability versus $\log[IC_{50}/IC_{50}(\text{wt})]$ for a series of fluorinated tryptophan derivatives at Trp183. Ondansetron fluorination plots for receptors activated by (a) mCPBG, and (b) 5-HT. Granisetron fluorination plots for receptors activated by (a) mCPBG, and (b) 5-HT. Red lines are linear fits ($y = mx + b$) inclusive of all points. Fit parameters (a) $m: -0.15 \pm 0.03$, $b: 5.1 \pm 0.6$, $R: 0.94$; (b) $m: -0.18 \pm 0.03$, $b: 6.0 \pm 0.8$, $R: 0.96$; (c) $m: -0.11 \pm 0.04$, $b: 3 \pm 1$, $R: 0.77$; (d) $m: -0.14 \pm 0.06$, $b: 5 \pm 2$, $R: 0.82$.


**Scheme 1.**

Table 1

EC₅₀ data for wild type and mutant 5-HT₃AR in response to 5-HT or mCPBG.

Agonist	Mutation	<i>N</i> ^a	EC ₅₀ (μM) ^b	Fold Shift ^c	Hill ^d
5-HT	Wild Type	25	1.6 ± 0.1	-	2.1 ± 0.2
	W183F ₁ W (5)	18	3.4 ± 0.2	2.2	2.0 ± 0.2
	W183F ₂ W (5,7)	11	18 ± 1	11	2.9 ± 0.2
	W183F ₂ W (4,7)	19	36 ± 2	23	2.2 ± 0.3
	W183F ₃ W (5,6,7)	10	250 ± 10	160	5 ± 1
	W90F ₃ W (5,6,7)	20	0.23 ± 0.01	1/6.8	2.0 ± 0.2
	W90F ₄ W (4,5,6,7)	29	0.64 ± 0.03	1/2.4	2.3 ± 0.2
mCPBG	Wild Type	9	0.50 ± 0.02	-	2.2 ± 0.1
	W183F ₁ W (5)	14	5.8 ± 0.4	12	1.6 ± 0.1
	W183F ₂ W (5,7)	9	2.6 ± 0.1	5.3	1.8 ± 0.1
	W183F ₂ W (4,7)	19	0.34 ± 0.03	1/1.5	1.4 ± 0.1
	W183F ₃ W (5,6,7)	13	6.6 ± 0.2	13	2.6 ± 0.2
	W183F ₄ W (4,5,6,7)	14	8.4 ± 0.6	17	1.5 ± 0.1
	W90F ₃ W (5,6,7)	15	0.092 ± 0.004	1/5.4	3.2 ± 0.5
	W90F ₄ W (4,5,6,7)	7	0.20 ± 0.02	1/2.5	2.1 ± 0.3

^aNumber of oocytes averaged in EC₅₀ determination.

^bThe effective concentration for half-maximal receptor activation.

^cEC₅₀(mutant)/EC₅₀(wild type).

^dThe Hill coefficient, *n*_H, as determined from fitting the Hill equation.

Table 2

IC₅₀ data for wild type and mutant 5-HT₃AR for granisetron and ondansetron in response to 5-HT or mCPBG.

Antagonist	Agonist ^a	Mutation	N ^b	IC ₅₀ (nM) ^c	Fold Shift ^d	Hill ^e
Granisetron	5-HT	Wild Type	27	0.78 ± 0.04	-	-1.4 ± 0.1
		W183F ₁ W (5)	17	2.9 ± 0.3	3.7	-1.4 ± 0.2
		W183F ₂ W (5,7)	14	100 ± 10	130	-1.7 ± 0.2
		W183F ₂ W (4,7)	11	3.4 ± 0.2	4.4	-1.6 ± 0.1
		W183F ₃ W (5,6,7)	9	61 ± 2	78	-1.6 ± 0.1
		W90F ₃ W (5,6,7)	11	0.20 ± 0.03	1/3.9	-1.1 ± 0.1
		W90F ₄ W (4,5,6,7)	12	0.64 ± 0.03	1/1.2	-1.8 ± 0.1
		Wild Type	27	1.5 ± 0.1	-	-1.5 ± 0.1
		W183F ₁ W (5)	8	3.3 ± 0.2	2.2	-1.4 ± 0.1
Granisetron	mCPBG	Wild Type	27	1.5 ± 0.1	-	-1.5 ± 0.1
		W183F ₁ W (5)	8	3.3 ± 0.2	2.2	-1.4 ± 0.1
		W183F ₂ W (5,7)	16	140 ± 10	93	-1.5 ± 0.1
		W183F ₂ W (4,7)	13	2.4 ± 0.3	1.6	-1.3 ± 0.2
		W183F ₃ W (5,6,7)	9	41 ± 2	27	-1.2 ± 0.1
		W183F ₄ W (4,5,6,7)	14	110 ± 10	74	-0.9 ± 0.1
		W90F ₃ W (5,6,7)	7	0.20 ± 0.02	1/7.6	-1.2 ± 0.1
		W90F ₄ W (4,5,6,7)	9	0.38 ± 0.04	1/4	-1.3 ± 0.2
		Wild Type	21	0.87 ± 0.04	-	-1.6 ± 0.1
Ondansetron	5-HT	Wild Type	21	0.87 ± 0.04	-	-1.6 ± 0.1
		W183F ₁ W (5)	16	6.2 ± 0.4	7.1	-1.5 ± 0.1
		W183F ₂ W (5,7)	11	140 ± 10	160	-2.2 ± 0.2
		W183F ₂ W (4,7)	9	67 ± 6	77	-1.7 ± 0.2
		W183F ₃ W (5,6,7)	9	160 ± 10	180	-1.8 ± 0.1
		W90F ₃ W (5,6,7)	13	0.40 ± 0.03	1/2.2	-1.3 ± 0.1
		W90F ₄ W (4,5,6,7)	11	1.3 ± 0.1	1.4	-1.7 ± 0.1
		Wild Type	23	0.91 ± 0.04	-	-1.5 ± 0.1
		W183F ₁ W (5)	15	10 ± 1	11	-1.9 ± 0.2
Ondansetron	mCPBG	Wild Type	23	0.91 ± 0.04	-	-1.5 ± 0.1
		W183F ₁ W (5)	15	10 ± 1	11	-1.9 ± 0.2
		W183F ₂ W (5,7)	13	140 ± 10	160	-1.3 ± 0.1
		W183F ₂ W (4,7)	13	73 ± 6	80	-1.7 ± 0.2

Antagonist	Agonist ^d	Mutation	N ^b	IC ₅₀ (nM) ^c	Fold Shift ^d	Hill ^e
		W183F ₃ W (5,6,7)	8	89 ± 5	99	-1.1 ± 0.1
		W183F ₄ W (4,5,6,7)	15	590 ± 80	650	-1.1 ± 0.1
		W90F ₃ W (5,6,7)	11	0.37 ± 0.03	1/2.4	-1.5 ± 0.2
		W90F ₄ W (4,5,6,7)	9	1.5 ± 0.1	1.6	-1.3 ± 0.1

^a Agonist used in the presence of antagonist for channel activation.

^b Number of oocytes averaged in IC₅₀ determination.

^c The effective concentration for half-maximal receptor inhibition.

^d IC₅₀(mutant)/IC₅₀(wild type).

^e The Hill coefficient. nH as determined from fitting the Hill equation.